How Much Does Cryodestruction Cost in China?
Cryodestruction in China typically costs from $2,200 to $4,800. The final price depends on the hospital tier, city, and whether the procedure targets superficial skin lesions or internal tumors. In the United States, similar procedures cost around $5,800 on average. Patients save around 40% compared to US rates. Standard packages usually include the surgical intervention, diagnostic imaging, and short-term hospital stays.
- Tumor cryoablation: $2,200 to $4,800 for minimally invasive organ-specific treatments.
- Medical hubs: Prices in Beijing and Guangzhou often run higher than in regional centers like Chengdu.
- Facility tier: Specialist oncology hospitals typically charge 20% more than general public facilities.
- Technology premiums: Advanced techniques like NanoKnife or argon-helium knife add to the total cost.
Bookimed Expert Insight: China offers exceptional value for complex oncology cases at JCI-accredited facilities. Fuda Cancer Hospital has performed over 10,000 cryosurgeries with costs approximately 2 to 3 times lower than Western Europe. Leading experts like Dr. Xiao Yueyong provide world-class care in Chengdu. Choosing these specialized centers ensures access to proprietary needle techniques and multidisciplinary care. Most specialized hospitals also provide free airport transfers and interpreters.
| China | Turkey | Austria | |
|---|---|---|---|
| Cryodestruction | ≈ $2,200 | from $500 | ≈ $1,400 |
Your Benefits and Guarantees with Bookimed
Transparent Prices & Flexible Installments
No hidden fees – just official clinic prices. Pay at the clinic for Cryodestruction upon arrival and use a flexible installment plan if needed.
Verified Clinics & Doctors Only
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Cryodestruction and have the necessary licenses to serve international patients worldwide.
Free 24/7 Assistance
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Cryodestruction journey.

Your personal Bookimed medical coordinator
- Supports you at every stage
- Helps choose the right clinic and doctor
- Ensures quick and convenient access to information
Discover the Best Cryodestruction Clinics in China: 1 Verified Option and Prices
Cryodestruction Overview in China
- Cryotherapy - from $7,500This therapy involves using cold temperatures to Remove abnormal tissue, relieve pain, and promote faster recovery.
- Cryotherapy for kidney cancer - from $15,000This therapy freezes kidney cancer cells, using thin probes introduced through small incisions, effective and minimally invasive.
Day 1 - Arrival
- Arrive in the country and settle in your accommodation.
- Visit the clinic for initial consultation.
Day 2 - Pre-Operation
- Meet with a specialist for medical history review.
- Undertake necessary tests, like blood and imaging tests.
- Discuss potential risks and benefits of Cryodestruction.
Day 3 - Cryodestruction
- Arrive at the clinic, fasted if advised.
- Undergo anesthesia, usually local or regional.
- Experience the Cryodestruction process, typically 1-2 hours.
- Return to your accommodation post-procedure.
Day 4 - Post-Operation
- Visit the clinic for a follow-up consultation.
- Discuss any immediate concerns or discomforts.
- Receive instructions for home care and potential medications.
Week 1-2 - Rehabilitation
- Rest and recover, avoiding strenuous activity.
- Keep the treatment area clean to prevent infection.
- Attend follow-up appointments for wound check and progress report.
Week 3-4 - Rehabilitation
- Gradually return to normal activities as comfort allows.
- Continue to attend follow-up appointments.
- By week 4, return to work may be possible depending on the job.
Week 5-6 - Rehabilitation
- Most patients should see the final result of the Cryodestruction.
- Return to sports and other strenuous activities if advised by your doctor.
Please note that this is a general guide and individual experiences may vary.
- Bookimed deposit: $200 or €200.
- Clinic deposit: Pay a set percentage in advance.
Our Doctors
View all Doctors
Liao Zhengyin
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.

Luo Xiaoping
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).

He Weibing
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.

Xiao Yueyong
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Video Stories from Bookimed Patients
Reviews about Bookimed: Discover Patients' Insights
All reviews


Share this content
Anna Leonova




